Clinical trials: Metastatic Liver Disease
Metastatic Colorectal Cancer
Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate
A study that is blinded to the patient and the investigator where the combination of Arfolitixorin + 5-FU is compared to Calciumfolinate + 5-FU.
- Trial name
- NCT04126655
- Testing
- Arfolitixorin
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Vastra Gotaland Region
Metastatic Cancer, Melanoma
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
This is a pilot study designed to evaluate the cutaneous effect of systemic inhibition of the tyrosine kinase pathway in the presence or absence of solar simulated light exposure.
- Conditions
- Metastatic Cancer, Melanoma, Colon Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03176485
- Testing
- Solar Simulator
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Arizona
Colorectal Cancer Metastatic, Colorectal Cancer
TheraSphere® For Treatment of Metastases in Liver
To investigate whether the dose predicted by pre-therapy 99mTc MAA SPECT predicts the dose to the liver from the 90Y microspheres as assessed by post-therapy 90Y SPECT/CT or positron emission tomography (PET)/CT.
- Trial name
- NCT04517643
- Testing
- Therasphere Therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Colorectal Cancer
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.
The study is designed to analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with bevacizumab combined with FOLFOX or FOLFIRI regimen in a prospective cohort and to…
- Trial name
- BEV-ONCO2012 (NCT01858649)
- Testing
- Metastases resection, Bevacizumab, 5 FU
- Where
- 11 sites in Belgium
- Volunteers
- 60 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Hepatocellular Carcinoma
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein…
- Trial name
- BANTAM-01 (NCT06764316)
- Testing
- BAY 3547926, BAY 3547922, BAY 3713391
- Where
- 36 sites in United States, Belgium and 7 more
- Volunteers
- 148 people
- Sponsor
- Bayer
Esophageal Neoplasms, Lung Neoplasms
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Background: Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect.
- Conditions
- Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms
- Trial name
- NCT02859415
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma
HCC is an aggressive, largely chemo-resistant cancer with a poor prognosis, currently there is no effective systemic chemotherapy for HCC.
- Trial name
- SECOX (NCT00752063)
- Testing
- Sorafenib with Capecitabine and Oxaliplatin
- Where
- China
- Volunteers
- 52 people
- Sponsor
- The University of Hong Kong
Rectal Cancer, Liver Metastasis
Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis
Radical treatment of primary rectal cancer with synchronous distant metastases includes surgical resection of primary and metastatic lesion.
- Conditions
- Rectal Cancer, Liver Metastasis, Lung Metastasis
- Trial name
- NCT01923987
- Testing
- Short Course Radiotherapy, Chemotherapy, Delayed Surgery
- Where
- 2 sites in South Korea
- Volunteers
- 39 people
- Sponsor
- Korea Cancer Center Hospital
Metastatic Colorectal Cancer
Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer
This study is for patients with metastatic colorectal cancer who are candidates for resection of metastases. This study will be conducted sequentially with 2 cohorts: 1.) Monotherapy Cohort and 2.) Combination Cohort…
- Trial name
- ATELIER (NCT03340558)
- Testing
- Atezolizumab, Cobimetinib
- Where
- United States
- Sponsor
- Niharika Mettu
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating children who have advanced…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00024258
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Primary Liver Cancer, Metastatic Liver Cancer
Improving CBCT for Liver IG-SBRT Using Gadoxetate Disodium
This is a feasibility study requiring only three patients to serve as a proof of concept that gadoxetate disodium (a liver specific contrast agent) can be used to improve images taken just before liver SBRT treatments.
- Trial name
- NCT03215355
- Testing
- Primovist
- Where
- Canada
- Sponsor
- Slawa Cwajna
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00009893
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- 19 sites in United States
- Volunteers
- 42 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Neoplasms, Liver Neoplasms
Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways
Background When first diagnosed, colorectal cancer has already metastasized in about 20% of patients to the liver or further (termed synchronous disease).
- Conditions
- Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
- Trial name
- CoSMIC (NCT02456285)
- Testing
- Primary/Bowel-first Surgery, Liver-first surgery, Synchronous resection surgery
- Where
- United Kingdom
- Volunteers
- 123 people
- Sponsor
- Manchester University NHS Foundation Trust
Colorectal Cancer, Metastatic Cancer
Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer
RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18-PET imaging, may be effective in detecting residual disease after radiofrequency ablation of liver metastases in patients with colorectal cancer.
- Trial name
- NCT00499395
- Testing
- positron emission tomography, radiofrequency ablation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatocellular Carcinoma, Metastatic Liver Cancers
A Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers
Liver cancer including primary hepatocellular carcinoma (HCC) and metastatic liver cancers is one the most common malignancies in the world. Over 10000 new cases per year are diagnosed in Taiwan.
- Trial name
- NCT02828865
- Testing
- Irreversible Electroporation (IRE) System
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- National Taiwan University Hospital
Ocular Melanoma, Uveal Melanoma
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
This study will evaluate patients who have ocular melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatments and will be followed until death.
- Trial name
- FOCUS (NCT02678572)
- Testing
- Melphalan/HDS
- Where
- 22 sites in United States, Austria and 7 more
- Volunteers
- 102 people
- Sponsor
- Delcath Systems Inc.
Hepatocellular Carcinoma
Non-contrast Abbreviated MRI for Secondary Surveillance of HCC
This prospective multicenter study aimed to compare the diagnostic performance of non-contrast abbreviated MRI in detecting recurrent HCC after curative treatment to that of contrast-enhanced liver CT.
- Trial name
- NCT05690451
- Testing
- non-contrast abbreviated MRI, Contrast enhanced liver CT
- Where
- 3 sites in South Korea
- Volunteers
- 210 people
- Sponsor
- Seoul National University Hospital
Colorectal Neoplasms, Drug Therapy
Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer
To evaluate the efficacy and safety of neoadjuvant FOLFOXIRI chemotherapy (irinotecan, oxaliplatin and fluorouracil) in the patients with resectable liver metastasis of colorectal cancer
- Trial name
- NCT03487939
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Portal Vein Thrombosis, Local Cause
Risk Factors for Recurrence of Thrombosis or Thrombotic Extension, in the Event of Acute Non-cirrhotic Portal Vein Thrombosis Secondary to a Local Cause.
In case of acute portal vein thrombosis (PVT) prothrombotic factors are identified in about 60% of cases, while a local condition is present in 30% of cases.
- Trial name
- LOCAPORT (NCT05360641)
- Where
- France
- Volunteers
- 154 people
- Sponsor
- University Hospital, Caen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.